Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

NYSEAM:LCTX - Post by User

Lineage Cell Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by schoolofrockon Nov 03, 2020 8:01am

117 Views

Post# 31828496

Nov 10th - Meet CEO Brian Culley and CFO Brandi Roberts

Mark your calendar - Nov 10th - virtual road show a week from today with CEO Brian Culley and CFO Brandi Roberts. Register at no charge:

https://attendee.gotowebinar.com/register/5866089557613760267

User image